Share on StockTwits

Shares of United Therapeutics (NASDAQ:UTHR) have received an average rating of “Hold” from the fifteen brokerages that are currently covering the company, AnalystRatingsNetwork.com reports. Six analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $96.00.

In other United Therapeutics news, COO Roger Jeffs sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $99.91, for a total transaction of $999,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

United Therapeutics (NASDAQ:UTHR) traded up 2.22% on Thursday, hitting $101.38. 112,785 shares of the company’s stock traded hands. United Therapeutics has a 52 week low of $61.23 and a 52 week high of $116.65. The stock’s 50-day moving average is $98.5 and its 200-day moving average is $98.93. The company has a market cap of $4.884 billion and a P/E ratio of 21.55.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, April 29th. The company reported $1.77 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter in the prior year, the company posted $1.19 earnings per share. The company’s quarterly revenue was up 18.1% on a year-over-year basis. On average, analysts predict that United Therapeutics will post $7.79 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics in a research note on Thursday, May 1st. They now have a $105.00 price target on the stock. Separately, analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. They now have a $118.00 price target on the stock.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.